There is a lot of noise around tirzepatide right now. Most of it is wrong.
Let me go through every real objection directly.
“It kills your motivation and drive.”
The opposite is true.
At therapeutic doses the clinical data does not support blunted motivation. What actually quiets is the compulsive, obsessive relationship with food. That bandwidth gets redirected to everything that actually matters.
The same mechanism that quiets food noise appears to reduce other compulsive reward-seeking behaviors. A 2023 study in the Journal of Clinical Investigation showed semaglutide significantly reduced alcohol intake in patients with alcohol use disorder.
Less compulsive is not less driven. Genuine motivation, genuine libido, and genuine ambition appear unaffected. The man who can direct his energy intentionally rather than being pulled around by compulsive urges is operating at a higher level, not a lower one.
The real motivation killer while cutting is low testosterone. That is what steals drive, ambition, and the will to attack the day. Not tirzepatide. That is why Mojo is non-negotiable on this protocol. Keep testosterone optimized and the drive does not just stay. It climbs.
“You will get desensitized to it. It will stop working.”
No. This is not how the mechanism works.
Tolerance happens when reward pathway receptors downregulate. Caffeine. Nicotine. Stimulants. GLP-1 and GIP receptors are metabolic receptors. They do not work this way. The SURMOUNT trial data at 72 weeks shows no meaningful tolerance development.
If hunger increases over time it is almost always one thing: lower leptin from lower body fat. That is not tolerance. That is your body getting lighter. A small dose adjustment handles it.
“The side effects are terrible.”
They can be if you do it wrong.
Almost all side effects are GI in nature and dose-dependent. Start at 1.5mg, titrate slowly, and most people feel nothing significant.
The cause nobody talks about is under-eating. Fall into too large a deficit and energy crashes, GI symptoms worsen, and muscle loss accelerates. Adequate protein, proper nutrition, the right supplements. That is what separates a smooth experience from a rough one.
“There are no long term studies.”
GLP-1 agonists have been in clinical use since 2005. Twenty years. Millions of patients. The most studied class of obesity medication in history.
But nobody asks for the long-term studies on staying at 18 percent body fat. Chronic inflammation. Cardiovascular disease. Declining insulin sensitivity. That data exists. We just call it getting older.
Cardiovascular protection from tirzepatide is documented independent of weight loss. Inflammation markers improve. Insulin sensitivity improves. The choice is not between tirzepatide with uncertainty versus a safe alternative. The alternative has very well documented long term consequences of its own.
“Won’t I lose all my muscle?”
Only without the right protocol.
The GIP receptor mechanism in tirzepatide has muscle-sparing properties. But the real protection comes from the training signal and the supplements. Push hard three days a week and you are telling your body to hold the muscle. Gains keeps recomposition happening. Mojo keeps testosterone climbing.
The men losing muscle on tirzepatide are not training, not eating enough protein, and not protecting their hormones. That is not the compound failing. That is the protocol failing.
“I heard it causes pancreatic cancer.”
This concern has been studied extensively. No causal relationship between tirzepatide and pancreatic cancer has been established in human trials.
The concern originated from rodent studies using doses far beyond therapeutic human doses. The human clinical data does not support this association. The FDA reviewed this extensively before approval and monitors it continuously in post-market surveillance.
“What about thyroid cancer and going blind?”
The thyroid concern applies to one specific genetic condition: MEN2, multiple endocrine neoplasia type 2. Physicians screen for this before prescribing. If you do not have this condition the risk does not apply to you.
The vision concern has been reported in a small number of cases, primarily in people with pre-existing diabetic eye conditions. In otherwise healthy individuals using low doses this risk is not established. Worth discussing with your physician if you have any pre-existing eye conditions.
“Does it cause bone loss?”
Rapid weight loss of any kind can reduce bone density if not managed correctly. The mitigation is straightforward. Resistance training is the single most powerful stimulus for bone density maintenance. Adequate calcium and vitamin D intake matters. Mojo already covers D3. Used correctly at a low dose with proper training and nutrition, bone loss is not a meaningful concern.
“This is only studied in overweight people. Does it apply to me?”
The GLP-1 and GIP pathways work the same regardless of starting body composition. For the already-lean man the use case is different. Not dramatic weight loss. Just removing the last layer of friction at the final 5 to 10 pounds where biology fights back hardest. The mechanism is sound and the early data is positive.
Used correctly at a low dose with the right protocol and physician supervision, every objection here has an answer.
Talk Soon,
Greg O’Gallagher
P.S.
I’m setting up the Kino Clinic to give members a way to access tirzepatide legally and safely through a licensed pharmacy.
If you want to be on the private list for when clinic access goes live, opt in here.
